[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354247-105":59,"doc-detail-354247-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","her2-mutant-non-small-cell-lung-cancer-podcast-knowledge-is-power","HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power","","In the first episode of a podcast series, HER2-mutant non-small cell lung cancer (NSCLC) is introduced within the broader lung cancer landscape. The discussion explains what makes HER2-mutant NSCLC distinct, covering epidemiology, biology, and molecular mechanisms that drive tumor growth. It outlines the evolution of precision medicine, HER2 as a therapeutic target, and how molecular profiling supports targeted therapy development. Updated strategies include antibody–drug conjugates and tyrosine kinase inhibitors, alongside challenges and opportunities shaping management of this aggressive subtype.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/her2-mutant-non-small-cell-lung-cancer-podcast-knowledge-is-power/354247/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/her2-mutant-non-small-cell-lung-cancer-podcast-knowledge-is-power/354247.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the podcast episode focus on?","Question",{"text":112,"@type":113},"The first episode focuses on the emerging landscape of HER2-mutant non-small cell lung cancer, explaining how it fits into the wider NSCLC context.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is HER2 considered an important therapeutic target in NSCLC?",{"text":117,"@type":113},"HER2 is described as an oncogene driver when genetic events such as mutations, insertions, or amplifications occur, making HER2 signaling an oncogenic pathway worth targeting.",{"name":119,"@type":110,"acceptedAnswer":120},"Which treatment approaches are highlighted for HER2-mutant NSCLC?",{"text":121,"@type":113},"The episode covers evolving precision medicine strategies, including antibody–drug conjugates and tyrosine kinase inhibitors, and reviews related challenges and opportunities.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354247,1790727874,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Targeted Oncology (2026) 21:315–319  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-026-01214-3  \nHER2‑Mutant Non‑Small Cell Lung Cancer Podcast: Knowledge Is Power  \nVivek Subbiah1 · Martin Dietrich2 · Xiuning Le3  \nReceived: 31 July 2025 / Accepted: 2 April 2026 / Published online: 26 May 2026 © The Author(s) 2026  \nAbstract  \nIn the first episode of our podcast series, we introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. We explain what makes HER2-mutant NSCLC unique, from its epidemiology and biology to the molecular mechanisms driving cancer growth. We discuss the evolution of precision medicine in NSCLC, the role of HER2 as a therapeutic target, and how advances in molecular profiling have enabled the development of targeted therapies. The episode also covers the latest treatment strategies, including antibody–drug conjugates and tyrosine kinase inhibitors, and reviews the challenges and opportunities that define this aggressive cancer subtype. This podcast aims to enhance understanding of HER2-mutant NSCLC and the evolving therapeutic landscape that is reshaping management strategies for this aggressive disease.  \n* Vivek Subbiah [viveksubbiah@outlook.com](viveksubbiah@outlook.com)  \n1 Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA  \n2 The US Oncology Network and Cancer Care Centers of Brevard, Orlando, FL, USA  \n3 The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \nThe podcast and transcript can be viewed below the abstract of the online version of the manuscript. Alternatively, the podcast can be downloaded here: [https://doi.org/10.6084/m9.figshare](https://doi.org/10.6084/m9.figshare). 31926153.  \n1 Podcast Transcript  \nDr. Subbiah: Hello, and welcome to today’s podcast, Knowledge Is Power: HER2-Mutant Non-Small Cell Lung Cancer. I'm Vivek Subbiah, medical oncologist and chief of early phase drug development from the Sarah Cannon Research Institute, Nashville, Tennesseea . Welcome, everyone. Today, we have Dr. Martin Dietrich and Dr. Xiuning Le. Dr. Dietrich and Dr. Le, can you please introduce yourselves?  \nDr. Le: This is Xiuning Le. I am an associate professor at MD Anderson in the Department of Thoracic Medical Oncology. I am also the deputy section chief. I am really glad to participate in today's episode of Knowledge Is Power.  \nDr. Dietrich: Hello, I am Dr. Martin Dietrich. I am a medical oncologist at the US Oncology Network with the Cancer Care Centers of Brevard in Orlando, Florida.  \nDr. Subbiah: Thank you so much, it is a pleasure and privilege to have you both. Today, we are going to have a  \nHER2-mutant non-small cell lung cancer overview. Knowledge Is Power. In the first episode of our podcast series, we introduce the emerging landscape of HER2-mutant non-small cell lung cancer, highlighting its place within the broader context of non-small cell lung cancer. We explain what makes HER2-mutant non-small cell lung cancer unique, from its epidemiology and biology to molecular mechanisms driving cancer growth. We discuss the evolution of precision medicine in non-small cell lung cancer, the role of HER2 as a therapeutic target, and how advancesin molecular profiling have enabled the development of targeted therapies. The episode also covers the latest treatment strategies, including antibody–drug conjugates and tyrosine kinase inhibitors. We also review the challenges and opportunities that define this aggressive cancer subtype. This podcast aims to enhance understanding of HER2-mutant non-small cell lung cancer and the evolving therapeutic landscape that is reshaping management strategies for this aggressive and deadly disease. After this brief introduction, I would like to open up the floor for discussion: what is nonsmall cell lung cancer? Dr. Le, can you give us a brief overview of lung cancer, cancer-related deaths, and why HER2? Fl","cbCainaTDu1nOsDn","https://ap.wps.com/l/cbCainaTDu1nOsDn","pdf",617545,"English","# Abstract\n## Episode overview\n## Unique biology and molecular mechanisms\n## Precision medicine and HER2 targeting\n## Treatment strategies and emerging challenges\n# Podcast transcript\n## Introductions and format\n## Overview of non-small cell lung cancer\n## Why focus on HER2","[{\"question\":\"What does the podcast episode focus on?\",\"answer\":\"The first episode focuses on the emerging landscape of HER2-mutant non-small cell lung cancer, explaining how it fits into the wider NSCLC context.\"},{\"question\":\"Why is HER2 considered an important therapeutic target in NSCLC?\",\"answer\":\"HER2 is described as an oncogene driver when genetic events such as mutations, insertions, or amplifications occur, making HER2 signaling an oncogenic pathway worth targeting.\"},{\"question\":\"Which treatment approaches are highlighted for HER2-mutant NSCLC?\",\"answer\":\"The episode covers evolving precision medicine strategies, including antibody–drug conjugates and tyrosine kinase inhibitors, and reviews related challenges and opportunities.\"}]","HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power | PDF",1790109721,13]